Although incretin-based therapies have not yet been tested in clinical trials of sepsis, it has been hypothesized that both incretin-mimetics [32] and DPP4 inhibitors [35] may exert positive pleiotropic effects on both inflammation and immunomodulation. Here, DPP4 is linked to Sepsis.